Niagen Bioscience (NAGE) Competitors $9.04 -0.31 (-3.32%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAGE vs. KYMR, MOR, IMVT, ALVO, CRNX, OGN, CPRX, GMTX, RARE, and MIRMShould you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Kymera Therapeutics (KYMR), MorphoSys (MOR), Immunovant (IMVT), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Niagen Bioscience vs. Its Competitors Kymera Therapeutics MorphoSys Immunovant Alvotech Crinetics Pharmaceuticals Organon & Co. Catalyst Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical Mirum Pharmaceuticals Kymera Therapeutics (NASDAQ:KYMR) and Niagen Bioscience (NASDAQ:NAGE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Is KYMR or NAGE more profitable? Niagen Bioscience has a net margin of 13.07% compared to Kymera Therapeutics' net margin of -409.07%. Niagen Bioscience's return on equity of 19.06% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-409.07% -30.11% -25.65% Niagen Bioscience 13.07%19.06%12.20% Which has more volatility and risk, KYMR or NAGE? Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Do institutionals & insiders hold more shares of KYMR or NAGE? 15.4% of Niagen Bioscience shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 9.4% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer KYMR or NAGE? Kymera Therapeutics currently has a consensus target price of $59.11, suggesting a potential upside of 37.60%. Niagen Bioscience has a consensus target price of $13.22, suggesting a potential upside of 46.24%. Given Niagen Bioscience's higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 3.10Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, KYMR or NAGE? Niagen Bioscience has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M59.43-$223.86M-$3.10-13.86Niagen Bioscience$99.60M7.15$8.55M$0.1753.18 Does the media refer more to KYMR or NAGE? In the previous week, Kymera Therapeutics had 7 more articles in the media than Niagen Bioscience. MarketBeat recorded 8 mentions for Kymera Therapeutics and 1 mentions for Niagen Bioscience. Kymera Therapeutics' average media sentiment score of 1.25 beat Niagen Bioscience's score of -0.38 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNiagen Bioscience beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Niagen Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAGE vs. The Competition Export to ExcelMetricNiagen BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$736.50M$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio53.1817.7428.8323.83Price / Sales7.15179.21372.0766.02Price / Cash158.0741.9535.4557.96Price / Book15.078.508.275.54Net Income$8.55M-$55.06M$3.25B$259.28M7 Day Performance-3.00%-3.99%-3.73%-4.68%1 Month Performance-28.14%9.58%4.29%4.36%1 Year Performance226.35%6.70%25.87%17.88% Niagen Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAGENiagen Bioscience1.0385 of 5 stars$9.04-3.3%$13.22+46.2%N/A$736.50M$99.60M53.18120Analyst DowngradeKYMRKymera Therapeutics3.5789 of 5 stars$44.07+0.8%$59.11+34.1%-3.4%$2.87B$47.07M-14.22170News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant1.6706 of 5 stars$16.62-0.2%$36.40+119.0%-45.6%$2.84BN/A-6.07120Upcoming EarningsALVOAlvotech3.3884 of 5 stars$9.28-4.5%$14.00+50.9%-24.0%$2.80B$491.98M25.081,032Positive NewsCRNXCrinetics Pharmaceuticals3.3272 of 5 stars$29.23-0.1%$69.50+137.8%-46.5%$2.74B$1.04M-7.65210News CoverageUpcoming EarningsOGNOrganon & Co.4.8732 of 5 stars$10.06-0.8%$18.00+78.9%-54.9%$2.62B$6.40B3.494,000Upcoming EarningsCPRXCatalyst Pharmaceuticals4.8982 of 5 stars$21.28+1.3%$32.83+54.3%+24.7%$2.60B$491.73M13.5580Positive NewsUpcoming EarningsGMTXGemini TherapeuticsN/A$59.80+0.5%N/A+38.5%$2.59BN/A-59.8030RAREUltragenyx Pharmaceutical4.474 of 5 stars$27.14-1.9%$82.57+204.2%-35.6%$2.57B$560.23M-4.621,294Upcoming EarningsAnalyst RevisionMIRMMirum Pharmaceuticals3.7255 of 5 stars$51.12-0.1%$65.50+28.1%+29.6%$2.53B$336.89M-31.75140News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies KYMR Competitors MOR Competitors IMVT Competitors ALVO Competitors CRNX Competitors OGN Competitors CPRX Competitors GMTX Competitors RARE Competitors MIRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAGE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
